Insert title here
    登录 | 注册 | 期刊登录 | 收藏
Clinical Chemistry 2013, Vol. 59 (1) :168 -179 doi:10.1373/clinchem.2012.184655 <<-上一篇 下一篇 ->>
Cell Plasticity and Heterogeneity in Cancer
Marjanovic, Nemanja D.1;Chaffer, Christine L.1;Weinberg, Robert A.1,2;
Marjanovic, Nemanja D.1;Chaffer, Christine L.1;Weinberg, Robert A.1,2;
Abstract: BACKGROUND: Heterogeneity within a given cancer arises from diverse cell types recruited to the tumor and from genetic and/or epigenetic differences amongst the cancer cells themselves. These factors conspire to create a disease with various phenotypes. There are 2 established models of cancer development and progression to metastatic disease. These are the clonal evolution and cancer stem cell models.
CONTENT: The clonal evolution theory suggests that successive mutations accumulating in a given cell generate clonal outgrowths that thrive in response to microenvironmental selection pressures, dictating the phenotype of the tumor. The alternative cancer stem cell (CSC) model suggests that cancer cells with similar genetic backgrounds can be hierarchically organized according to their tumorigenic potential. Accordingly, CSCs reside at the apex of the hierarchy and are thought to possess the majority of a cancer's tumor-initiating and metastatic ability. A defining feature of this model is its apparent unidirectional nature, whereby CSCs undergo symmetric division to replenish the CSC pool and irreversible asymmetric division to generate daughter cells (non-CSCs) with low tumorigenic potential. However, evolving evidence supports a new model of tumorigenicity, in which considerable plasticity exists between the non-CSC and CSC compartments, such that non-CSCs can reacquire a CSC phenotype. These findings suggest that some tumors may adhere to a plastic CSC model, in which bidirectional conversions are common and essential components of tumorigenicity.
SUMMARY: Accumulating evidence surrounding the plasticity of cancer cells, in particular, suggests that aggressive CSCs can be created de novo within a tumor. Given the current focus on therapeutic targeting of CSCs, we discuss the implications of non-CSC-to-CSC conversions on the development of future therapies. (C) 2012 American Association for Clinical Chemistry
Insert title here
更多服务: 作者自存档 | 投稿导航 | 全球期刊检索 | 查找审稿人
关于我们 | 隐私申明 | 免责声明 | 意见反馈 | 合作服务
Magsci ©  版权所有
Copyright © 2010 - 2013 Magtech. All Rights Reserved.